Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumors.

Study Overview

• Status: Completed
• Conditions: Central Nervous System Tumor, Pediatric
• Intervention / Treatment: Drug: cyclophosphamide; Drug: leucovorin calcium; Radiation: radiation therapy; Drug: temozolomide; Drug: cytarabine; Drug: etoposide; Drug: methotrexate; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Drug: cisplatin; Drug: doxorubicin hydrochloride; Biological: filgrastim; Drug: dexrazoxane hydrochloride; Drug: Dactinomycin

Detailed Description

OBJECTIVES:

Primary

• Determine the efficacy of intensive systemic and intrathecal chemotherapy and radiotherapy, in terms of medial survival, in children with newly diagnosed central nervous system atypical teratoid/rhabdoid tumors in comparison with historical outcomes from prior trials.

Secondary

• Determine the toxicity profile and tolerability of this regimen in these patients.
• Determine the chemosensitivity of these patients' tumors by Magnetic Resonance Imaging (MRI) after an attempt at maximum surgical resection after 2 courses of this regimen.
• Determine the predictive value of the INI-1 gene mutation in determining prognosis by comparing tumor samples from patients with vs without this mutation treated with this regimen.

STATISTICAL DESIGN: This was a single arm design evaluating median overall survival. The chosen historical control estimate of 7 months was based on 2 large multi-institutional studies in a similar setting and the alternative of 20.5 months based on a DFCI pilot study. There was 90% power to detect this improvement assuming 1-sided 0.10 alpha and 17 eligible patients. Sample size (n=20 patients) was inflated for expected 10-15% ineligible rate.

TREATMENT: Induction chemotherapy was required to be initiated within 50 days of the most definitive surgery.

• Central Nervous System (CNS)/intrathecal therapy: All patients with M0 disease receive triple intrathecal (IT) chemotherapy comprising methotrexate (MTX), cytarabine, and hydrocortisone on day 1 of weeks 1, 2, 4, 7, 13, 19, 27, 33, 39, 45, and 51 followed by oral or intravenous (IV) leucovorin calcium given 24 hours after each MTX dose. Patients with initially positive cerebrospinal fluid (CSF) cytology (M+) receive triple IT chemotherapy weekly until 2 consecutive CSF samples are negative for malignant cells.
• Pre-irradiation induction therapy (weeks 1-6): Patients receive vincristine IV on day 1 of weeks 1-6; cisplatin IV over 8 hours on day 1 and doxorubicin IV continuously over 48 hours beginning on day 2 of weeks 1 and 4; cyclophosphamide IV continuously over 72 hours beginning on day 2 of week 1; etoposide IV over 1 hour on days 1-3 of week 4; and filgrastim (G-CSF) subcutaneously (SC) beginning on day 6 of week 1 and day 4 of week 4 and continuing until blood counts recover.
• Induction chemoradiotherapy (weeks 7-12): Patients receive vincristine IV on day 1 of weeks 7-12; cisplatin IV over 8 hours on day 1, cyclophosphamide IV over 1 hour on day 2, etoposide IV over 1 hour on days 1-3 of weeks 7 and 10; and granulocyte-colony stimulating factor (G-CSF) subcutaneous (SC) daily beginning on day 4 of weeks 7 and 10 and continuing until blood counts recover. Patients with M0 disease and patients under 3 years of age with M+ disease undergo radiotherapy to the primary tumor daily on weeks 7-12. Patients 3 years of age and over with M+ disease undergo craniospinal irradiation (CSI) daily on weeks 7-12 until negative cerebral spinal fluid (CSF) cytology is achieved.
• Post-radiation induction therapy (weeks 13-18): Patients receive vincristine IV on day 1 of weeks 13 and 16; doxorubicin and cyclophosphamide as in pre-irradiation induction therapy beginning on day 1 of week 13; cyclophosphamide IV over 1 hour on days 1-3 of week 16; dactinomycin IV on days 1-5 of week 16; and G-CSF SC daily beginning on day 6 of weeks 13 and 16 and continuing until blood counts recover.
• Maintenance chemotherapy (weeks 19-42): Patients receive vincristine IV on day 1 of weeks 27, 33, and 39 and days 1 and 5 of weeks 30, 36, and 42; doxorubicin and cyclophosphamide as in pre-irradiation induction beginning on day 1 of weeks 27 and 33; doxorubicin IV over 15 minutes and dexrazoxane (DX) IV over 15 minutes on days 1 and 2 of week 39; cyclophosphamide IV over 1 hour on days 1-3 of weeks 30, 36, 39, and 42; dactinomycin IV on days 1-5 of weeks 30, 36, and 42 and on day 1 of weeks 19 and 23; oral temozolomide on days 1-5 of weeks 19 and 23; and G-CSF SC daily beginning on day 6 of weeks 19, 23, 30, 36, and 42, day 5 of weeks 27 and 33, and day 4 of week 39 and continuing until blood counts recover.
• Doxorubicin continuation therapy (for patients not receiving CSI and mediastinal radiotherapy)(weeks 45-51): Patients receive vincristine IV on day 1 of weeks 45, 48, and 51 and day 5 of week 48; doxorubicin IV over 15 minutes and DX IV over 15 minutes on days 1 and 2 of weeks 45 and 51; cyclophosphamide IV over 1 hour on days 1-3 of weeks 45, 48, and 51; dactinomycin IV on days 1-5 of week 48; and G-CSF SC daily beginning on day 4 of weeks 45 and 51 and day 6 of week 48 and continuing until blood counts recover.
• Non-doxorubicin continuation therapy (for patients receiving CSI or mediastinal radiotherapy)(weeks 45-51): Patients receive cyclophosphamide and G-CSF as in doxorubicin continuation therapy; vincristine IV on days 1 and 5 of weeks 45, 48, and 51; and dactinomycin IV on days 1-5 of weeks 45, 48, and 51.

Treatment continues in the absence of disease progression or unacceptable toxicity.

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Stanford, California, United States, 94305-5826
      • Stanford Cancer Center
  • Connecticut
    • New Haven, Connecticut, United States, 06520-8028
      • Yale Cancer Center
  • Georgia
    • Atlanta, Georgia, United States, 30342
      • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus
  • Illinois
    • Chicago, Illinois, United States, 60614
      • Children's Memorial Hospital - Chicago
  • Maryland
    • Baltimore, Maryland, United States, 21231-2410
      • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Children's Hospital Boston
    • Boston, Massachusetts, United States, 02115
      • Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
  • Minnesota
    • Minneapolis, Minnesota, United States, 55404
      • Children's Hospitals and Clinics of Minnesota - Minneapolis
  • Nevada
    • Las Vegas, Nevada, United States, 89109
      • Sunrise Hospital and Medical Center
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic Taussig Cancer Center
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Children's Hospital of Philadelphia
  • Texas
    • Dallas, Texas, United States, 75390
      • Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 16 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

DISEASE CHARACTERISTICS:

• Histologically confirmed primary intracranial Central Nervous System (CNS) atypical teratoid/rhabdoid tumor OR
• Tumor tissue that possesses the INI-1 gene mutation

• No metastases that disseminate outside the CNS by abdominal and chest computer tomography (CT) scans, kidney imaging, and bone marrow biopsy

  • No obstruction of cerebrospinal fluid (CSF) flow by CSF flow study
• Definitive surgical resection of tumor within the past 35 days

PATIENT CHARACTERISTICS:

Age

• 18 and under

Performance status

• Karnofsky 50-100% OR
• Lansky 50-100%

Life expectancy

• Not specified

Hematopoietic

• Hemoglobin > 10 g/dL
• Absolute neutrophil count > 1,000/mm^3
• Platelet count > 100,000/mm^3

Hepatic

• Bilirubin ≤ 1.5 mg/dL
• SGPT < 10 times normal

Renal

• Creatinine ≤ 1.5 times normal

Other

• Willing to have placement of central venous access line

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• No prior chemotherapy

Endocrine therapy

• Prior steroids allowed

Radiotherapy

• No prior radiotherapy

Surgery

• See Disease Characteristics

Other

• No other prior or concurrent investigational agents
• Concurrent anticonvulsant agents allowed

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Multi-agent Intrathecal and Systemic CT with RT (mod IRS III); Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51) Induction Chemotherapy: CT backbone of the IRS-III regimen [vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine, and hydrocortisone, coinciding with a cycle of CT. Radiation Therapy: Pts w/ M0 dz OR M+ dz aged <3y received focal RT (3D conformal or intensity-modulated delivery). Pts >3y w/ M+ dz rcvd craniospinal irradiation. Continuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively.

Drug: cyclophosphamide; Other Names: Cytoxan; CPM; Ciclofosfamida; Ciclofosfamide; Clafen; Claphene; CP monohydrate; Cyclophospham; Cyclophosphamid monohydrate; Cyclophosphamidum; Cyclophosphan; Cyclophosphanum; Cytophosphane; Mitoxan; Neosar; Syklofosfamid; Zytoxan; Drug: leucovorin calcium; Other Names: folinic acid; folinate calcium; Radiation: radiation therapy; Drug: temozolomide; Other Names: Temodar, Methazolastone, Temodal, TMZ, CCRG-81045; Drug: cytarabine; Other Names: Cytosar-U; Tarabine PFS; cytosine arabinoside; arabinofuranosylcytosine; arabinosylcytosine; aracytidine; beta-cytosine arabinoside; cytarabine hydrochloride; cytarabinum; cytosine arabinosine hydrochloride; Drug: etoposide; Other Names: VP-16; Drug: methotrexate; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Other Names: leurocristine sulfate; Vincasar PFS; Drug: cisplatin; Other Names: Cismaplat; Platinol; Cis-dichloroammine Platinum (II); CACP; cis-DDP; cis-diamminedichloroplatinum; cis-diamminedichloro platinum (II); Drug: doxorubicin hydrochloride; Other Names: Adriamycin PFS; Adriamycin RDF; Biological: filgrastim; Other Names: G-CSF; filgrastim XM02; Drug: dexrazoxane hydrochloride; Other Names: Totect; Zinecard; Drug: Dactinomycin; Other Names: AD; ACT-D; actinomycin C1; actinomycin D; actinomycin I1; actinomycin IV; actinomycin X 1; actinomycin-[thr-val-pro-sar-meval]; dactinomycine; meractinomycin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
2-yr Overall Survival	Overall survival is defined as the time from date of diagnosis to death or date of last follow-up. 2-year overall survival is the probability of patients remaining alive at 2-years from study entry estimated using Kaplan-Meier (KM) methods which censors patients at date of last follow-up. Precision of this conditional probability estimate was measured in terms of standard error. Median OS, the original primary endpoint, was not estimable based on the Kaplan-Meier method because of insufficient follow-up.	Patients are followed for survival up to 5 yrs post-therapy completion or death; As of this analysis, median follow-up among survivors was 31 months with the longest follow-up being 40 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pre-Radiation Therapy Chemotherapeutic Response	Response pre-RT/post-CT was defined as follows with overall response defined as achieving PR or CR. Complete Response (CR): Complete resolution of all initially demonstrable tumor on MRI or CT evaluation w/o appearance of any new areas of disease; negative CSF cytology. Partial Response (PR): >/= 50% decrease in the sum of the products of the maximum perpendicular diameters of the tumor (sum LD) relative to baseline w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Stable Disease (SD): <50% decrease in the sum LD w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Progressive Disease (PD): >/= 25% increase in the sum LD relative to baseline, or the appearance of any new areas of disease or appearance of positive cytology after two consecutive negative samples.	Assessed at study entry and pre-RT/post-CT at week 7.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Grade 3/4 Events	All Grade 3-4 events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Auditory/Hearing Events	All Grade 3-4 Auditory/Hearing events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Blood/Bone Marrow Events	All Grade 3-4 Blood/Bone Marrow events based on CTCAEv2 as reported on case report forms. Arm Name	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Gastrointestinal Events	All Grade 3-4 Gastrointestinal events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Metabolic/Laboratory Events	All Grade 3-4 Metabolic/Laboratory events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Infection/Febrile Neutropenia Events	All Grade 3-4 Infection/Febrile Neutropenia events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Neurology Events	All Grade 3-4 Neurology events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Pain Events	All Grade 3-4 Pain events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Constitutional Events	All Grade 3-4 Constitutional events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Muscloskeletal Events	All Grade 3-4 Muscloskeletal events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Hepatic Events	All Grade 3-4 Hepatic events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Cardiovascular Events	All Grade 3-4 Cardiovascular events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Pulmonary Events	All Grade 3-4 Pulmonary events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Renal/Genitourinary Events	All Grade 3-4 Renal/Genitourinary events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Dermatology Events	All Grade 3-4 Dermatology events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Hemorrhage Events	All Grade 3-4 Hemorrhage events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
Grade 3-4 Allergy/Immunology	All Grade 3-4 Allergy/Immunology events based on CTCAEv2 as reported on case report forms.	Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Collaborators and Investigators

• Sponsor: Dana-Farber Cancer Institute
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Mark W. Kieran, MD, PhD, Dana-Farber Cancer Institute

Publications and helpful links

General Publications

• Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE, Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L, Ullrich NJ, Kieran MW. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009 Jan 20;27(3):385-9. doi: 10.1200/JCO.2008.18.7724. Epub 2008 Dec 8.

Study record dates

Study Major Dates

• Study Start: February 1, 2003
• Primary Completion (Actual): February 1, 2008
• Study Completion (Actual): March 1, 2013

Study Registration Dates

• First Submitted: June 10, 2004
• First Submitted That Met QC Criteria: June 10, 2004
• First Posted (Estimate): June 11, 2004

Study Record Updates

• Last Update Posted (Estimate): December 24, 2015
• Last Update Submitted That Met QC Criteria: December 18, 2015
• Last Verified: December 1, 2015

More Information

Terms related to this study

• Keywords: childhood atypical teratoid/rhabdoid tumor
• Additional Relevant MeSH Terms: Nervous System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Complex and Mixed; Nervous System Neoplasms; Central Nervous System Neoplasms; Rhabdoid Tumor; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-Inflammatory Agents; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Protective Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Cardiotonic Agents; Dermatologic Agents; Micronutrients; Anti-Bacterial Agents; Adjuvants, Immunologic; Protein Synthesis Inhibitors; Antibiotics, Antineoplastic; Vitamins; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Reproductive Control Agents; Antidotes; Vitamin B Complex; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Folic Acid Antagonists; Cyclophosphamide; Etoposide; Cisplatin; Temozolomide; Leucovorin; Calcium; Levoleucovorin; Lenograstim; Doxorubicin; Liposomal doxorubicin; Cytarabine; Methotrexate; Vincristine; Calcium, Dietary; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate; Dexrazoxane; Razoxane; Dactinomycin
• Other Study ID Numbers: 02-294 DFCI; P30CA006516 (U.S. NIH Grant/Contract)